Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Fosun International Limited
  6. News
  7. Summary
    656   HK0656038673


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Nature: Making Biologic Medicines More Accessible

11/23/2021 | 03:39am EST
Nature: Making Biologic Medicines More Accessible
Release Time:2021-11-22Author:Source: Pageviews:

Global biopharmaceutical company Henlius aims to greatly improve patient well-being with affordable and innovative biologic medicines.

Henlius has built an integrated biopharmaceutical platform with high efficiency and innovation embedded throughout the product life cycle.Credit: Henlius

Patients with cancer or autoimmune diseases often deal with long periods of debilitating symptoms with the conditions sometimes life-threatening. Even those fortunate enough to find an effective treatment may face the hurdle of high costs.

Recognizing these challenges, and personally experiencing the loss of a loved one to cancer, two biologists and Fosun Pharma founded Henlius in 2010 with a vision of offering high-quality, affordable and innovative biologic medicines with a focus on cancer, autoimmune diseases and ophthalmic diseases.

Xuhui Manufacturing Facility is certificated by China and the EU GMP.Credit: Henlius

An alternative to costly biologics

Henlius has made great advances in the field of biosimilars. These, as the name suggests, are designed to be very similar to brand-name drugs in their clinical effect, but are lower in cost. They can be made available when pharmaceutical companies' exclusive patents on drugs expire.

Biosimilars are not to be confused with generic drugs, which are also marketed as an affordable alternative to brand-name drugs. Biosimilars are modelled after drugs that are biological, also known as biologics, meaning they use living organisms as ingredients. Generic drugs, however, are identical copies of synthetic drugs that are created using a chemical process.

The complexity and costs of developing biosimilars are much higher than developing generic drugs, explains Jason Zhu, chief medical officer and senior vice president of Henlius. "Biosimilars are comprised of large complex molecules, while generic drugs consist of small molecules," says Zhu. "To develop biosimilars typically takes around 7-8 years and US$100-300 million, while to develop generic drugs usually takes about 2-3 years and US$2-3 million.

Biosimilars are rising in demand, notes Zhu, despite the higher costs and technology requirements involved in their development. This is because biologics are increasingly proving to be effective treatments for certain diseases. Also, the patents of many biologics are due to expire, making it an opportune time for the development and introduction of biosimilars to offset drug prices.

For example, consider therapeutics for HER2 positive breast cancer. "In the past, HER2 positive breast cancer was almost untreatable, and patients suffered a lot," says Zhu. "The introduction of biologic trastuzumab in 1998 provided a life-saving alternative for the treatment of this deadly disease."

However, trastuzumab is a costly drug, so this is where biosimilars can fill the gap, says Zhu.

"With biosimilars, we can bring down the price of such drugs significantly as the market will no longer be exclusively dominated by the branded drug. This benefits patients the most," he adds.

There are now several biosimilars for trastuzumab in the market, including one launched by Henlius and approved by both the European Commission and China's National Medical Products Administration (NMPA) in 2020. The biosimilar has undergone a global Phase III clinical study and been demonstrated as highly similar to trastuzumab in terms of quality, safety and efficacy. In addition to China, the biosimilar has been launched in European countries including France, Germany, Hungary, Ireland, Italy, Spain and Switzerland.

Besides trastuzumab, Henlius has also launched two other biosimilars, including one for rituximab in 2019 and another for adalimumab in 2020. Zhu explains that the Rituximab biosimilar is the first biosimilar to come to market in the country.

More than 70,000 Chinese patients have benefited from biosimilars produced by Henlius.

Henlius has research centres in California and Shanghai and development teams in the US and China.Credit: Henlius

Think big and go global

Going forward, Zhu says, Henlius hopes to expand its global reach and help more patients tackle life-threatening diseases. The company has built an integrated biopharmaceutical platform with high efficiency and innovation embedded throughout the product life cycle, including R&D, manufacturing and commercialization. Meanwhile, the company has invested globally in talent, including research centres in both California and Shanghai and development teams in the US and China. On this basis, Henlius has joined forces to upgrade marketed products like bevacizumab by optimizing the prescription, specifications and production processes.

In 2022, Henlius plans to launch Serplulimab, an immunotherapy drug that targets the PD-1 receptor. "One of the indications of Serplulimab is to help patients with high levels of MSI, a cancer biomarker. This means the drug can target many types of cancers, such as endometrial cancer, colorectal cancer and gastric cancer, potentially benefiting a large population," says Zhu.

Other indications for Serplulimab include the treatment of non-small cell lung cancer and small cell lung cancer. Zhu says Henlius has already submitted applications to China's NMPA for the first two indications. He outlines plans to submit applications, leveraging the clinical data from global multi-centre clinical trials, to authorities abroad, such as the US Food and Drug Administration (FDA), and hopes to launch this drug in overseas markets.

"What's really exciting is that as we receive more clinical data for Serplulimab, we are gaining confidence that we own one of the best molecules in the PD-1 class," he says. "In addition, Henlius has a proven manufacturing capability for reliable product supply. Every day, we are determined to serve more patients in need."


Fosun International Limited published this content on 22 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 November 2021 08:38:03 UTC.

ę Publicnow 2021
01/18FOSUN INTERNATIONAL : Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Di..
01/13FOSUN INTERNATIONAL : Ranks Fourth in “Hurun China Private Companies SDG Readiness 1..
01/12FOSUN INTERNATIONAL : Hospital da Luz Lisboa with Maximum Rating of Clinical Excellence
01/10FOSUN'S INTELLIGENT MANUFACTURING : China's First Privately-owned High-speed Railway Start..
01/06FOSUN INTERNATIONAL : MSCI ESG ratingupgraded to AA
01/05GUO GUANGCHANG NEW YEAR'S SHARING : Believe in the Power of Perseverance
2021FOSUN INTERNATIONAL : Shede Gala Concert Spreads Love and Charity Through Music
2021ONE FOSUN CSR WEEK : Fosun Global Philanthropic Campaigns Sending Warmth and Love to All
2021ONE FOSUN CSR WEEK : Fosuners Bring Warmth to the World with Global Philanthropic Campaign..
2021FOSUN INTERNATIONAL : Receives “ESG Communications Award” at the PR Newswire N..
More news
Analyst Recommendations on FOSUN INTERNATIONAL LIMITED
More recommendations
Sales 2021 155 B 24 445 M 24 445 M
Net income 2021 12 012 M 1 895 M 1 895 M
Net Debt 2021 126 B 19 871 M 19 871 M
P/E ratio 2021 4,92x
Yield 2021 4,67%
Capitalization 59 746 M 9 426 M 9 425 M
EV / Sales 2021 1,20x
EV / Sales 2022 1,13x
Nbr of Employees 78 000
Free-Float 27,2%
Duration : Period :
Fosun International Limited Technical Analysis Chart | 656 | HK0656038673 | MarketScreener
Technical analysis trends FOSUN INTERNATIONAL LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 10
Last Close Price 7,19 CNY
Average target price 10,65 CNY
Spread / Average Target 48,2%
EPS Revisions
Managers and Directors
Qi Yu Chen Co-Chief Executive Officer & Executive Director
Xiao Liang Xu Co-Chief Executive Officer & Executive Director
Ping Gong Chief Financial Officer & Executive Director
Hou Lin Zhang Co-Chief Financial Officer & Senior Vice President
Li Gang Zhang Co-CFO & GM-Financial Management
Sector and Competitors
1st jan.Capi. (M$)
ALLIANZ SE6.77%102 705
CHUBB LIMITED-0.67%82 733